These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8856307)

  • 21. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer.
    Davis-Perry S; Hernandez E; Houck KL; Shank R
    Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
    Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
    J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation.
    Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ
    J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.
    Miller DS; Brady MF; Barrett RJ
    Am J Clin Oncol; 1992 Apr; 15(2):125-8. PubMed ID: 1553899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
    Nardi M; Aloe A; De Marco S; Cognetti F; Iacovelli A; Atlante G; Calabresi F
    Am J Clin Oncol; 1997 Jun; 20(3):230-2. PubMed ID: 9167742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
    Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
    Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.